Marché mondial de la thérapie par facteur de croissance des protéines morphogénétiques osseuses – Tendances et prévisions de l'industrie jusqu'en 2029

Analyse et perspectives du marché mondial de la thérapie par facteur de croissance des protéines morphogénétiques osseuses

Les protéines morphogénétiques osseuses (BMP) sont des facteurs de croissance qui favorisent la formation osseuse après une fracture. De plus, ces protéines jouent un rôle essentiel au cours du développement embryonnaire dans la formation du squelette. Il existe vingt variantes de BMP qui ont été découvertes jusqu'à présent, dont seulement deux, BMP-2 et BMP-7, ont été commercialisées comme substituts de greffe osseuse pour une utilisation dans des procédures orthopédiques spécifiques .

• Les BMP jouent un rôle important dans la formation des os et des cartilages, ainsi que dans l'embryogenèse. Data Bridge Market Research analyse que le marché de la thérapie par facteur de croissance des protéines morphogénétiques osseuses connaîtra un TCAC de 4,9 % au cours de la période de prévision de 2022 à 2029.

Portée du rapport et segmentation du marché

Dynamique du marché de la thérapie par facteur de croissance des protéines morphogénétiques osseuses

Conducteurs

Les principaux facteurs qui devraient stimuler la croissance du marché de la thérapie par facteur de croissance à base de protéines morphogénétiques osseuses dans les prévisions sont les suivants :

• The Rise in the Sports Regarding Injuries Around the World

Growing number of cases of sports injuries such as spinal injuries. The lumbar and cervical vertebrae of the spine are particularly vulnerable and require fusion which is one of the contributing factor for the market growth.

• The Growing Incidence for Minimally Invasive Procedures

Increasing cases of spinal fusion incidences, small bone surgeries, and trauma upsurge the rise in the cases of minimally invasive procedures particularly in the low back pain and spinal disc dislocation.

• The Technological Developments

Research and development is a key aspect of the company's growth strategy. Manufacturing businesses have conducted substantial study into the therapeutic potential of BMP in different orthopaedic conditions, such as osteoarthritis and soft tissue healing.

Additionally, the rising knowledge regarding the bone morphogenetic protein growth factor therapy is further estimated to cushion the growth of the bone morphogenetic protein growth factor therapy market.

Opportunities

In addition, the suitable reimbursement policies will further provide potential opportunities for the growth of the bone morphogenetic protein growth factor therapy market in the coming years.

Restraints/Challenges Global Bone Morphogenetic Protein Growth Factor Therapy Market

On the other hand, the increased expenses of the procedure is further projected to impede the growth of the bone morphogenetic protein growth factor therapy market in the timeline period. However, accessibility of substitute treatment might further challenge the growth of the bone morphogenetic protein growth factor therapy market in the near future.

This bone morphogenetic protein growth factor therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on bone morphogenetic protein growth factor therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The bone morphogenetic protein growth factor therapy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Bone Morphogenetic Protein Growth Factor Therapy Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market.

Recent Development

• In September 2019, Medtronic, an Irish medical device company, stated that pivotal, randomised, and prospective clinical trials for the use of Infuse bone graft have been approved by the FDA. The findings of the study could lead to the use of bone transplant in TLIF (Transforaminal Lumbar Interbody Fusion) spine operations.

Global Bone Morphogenetic Protein Growth Factor Therapy Market Scope

The bone morphogenetic protein growth factor therapy market is segmented on the basis of type and application. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Recombinant Human Bone Morphogenetic Protein (rhBMP)-2
• Recombinant Human Bone Morphogenetic Protein (rhBMP)-7

On the basis of type, the bone morphogenetic protein growth factor therapy market is segmented into recombinant human bone morphogenetic protein (rhBMP)-2 and recombinant human bone morphogenetic protein (rhBMP)-7.

Application

• Spinal Fusion
• Trauma
• Reconstructive Surgery
• Oral-Maxillofacial
• Others

On the basis of treatment, the bone morphogenetic protein growth factor therapy market is segmented into spinal fusion, trauma, reconstructive surgery, oral-maxillofacial and others.

Pipeline Analysis

The rhBMP-2 and rhBMP-7 are also used in the treatment of variety of bone related condition specially rsBMP-2 is extensively used in lumbar spinal fusion technique such as antierior and posterior survical fusion pipeline analysis of anticonvulsant drugs includes various pipeline therapies such as LP352, OPC-214870, Ganaxolone, CT-010, Vatiquinone E-2730, XEN496, and NBI 827104. Medtronic, Stryker, Merck KGaA, Prospec-Tany Technogene Ltd., Ember Therapeutics and others are the involved in the development of potential drugs for the development of cytokines and metabologens.

Bone Morphogenetic Protein Growth Factor Therapy Market Regional Analysis/Insights

The bone morphogenetic protein growth factor therapy market is analysed and market size insights and trends are provided by country, type and application as referenced above.

The countries covered in the bone morphogenetic protein growth factor therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the bone morphogenetic protein growth factor therapy market due to the rise in the adoption of advanced technology. Furthermore, the suitable reimbursement policies will further boost the growth of the bone morphogenetic protein growth factor therapy market in the region during the forecast period.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Bone Morphogenetic Protein Growth Factor Therapy Market Share Analysis

The bone morphogenetic protein growth factor therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to bone morphogenetic protein growth factor therapy market.

Some of the major players operating in the bone morphogenetic protein growth factor therapy market are:

• Medtronic (US)
• Stryker Corporation (US)
• Merck KGaA (Germany)
• Prospec-Tany Technogene Ltd. (Israel)
• Ember Therapeutics. (US)
• R&D Systems, Inc (US)
• Thermo Fisher Scientific (US)
• Akron Biotechnology LLC (US)
• Sino Biological Inc (China)

SKU-52705